ReviewEndocrine-related cancer2025
Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?
Review in Endocrine-related cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The topic proposed asks why we have an incomplete understanding of estrogen receptor (ER) action in cancer. We agree that the role of ER in some cancers is poorly understood, but the role of ER in luminal breast cancer (which represents the biggest subtype of the most common cancer in women) is very well characterised. Although technologies evolve and allow us to learn more about the intricacies of the genome and the multitude of ways breast cancer can adapt to bypass treatments, our understanding of how ER regulates gene expression is extraordinary. We would posit that the key events in ER-mediated cell cycle progression are already known and although new information adds granular information to our paradigms of ER action, we need to better characterise what has been discovered already.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.